Team Management of High Blood Pressure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

179 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-07-31

Study Completion Date

2006-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test whether blood pressure control can be improved by physician education and feedback provided through the development of physician/pharmacist collaborative teams.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Improving Adherence to Blood Pressure Guidelines

NCT00201019

Hypertension

COMPLETED NA

Improving Practice Patterns for the Treatment of Hypertension

NCT00265044

Hypertension

COMPLETED NA

A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities

NCT00935077

Hypertension Asthma

COMPLETED PHASE3

Trial of Low and High Intensity Strategies to Maintain BP Control

NCT00760552

Hypertension

COMPLETED NA

Implementing Evidence Based Treatment of Hypertension

NCT00265538

Hypertension

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND:

The Healthy People 2010 target calls for controlled BP in 50% of the 50 million Americans with hypertension. BP is currently controlled in only 27% of the population. These population figures are in contrast to data from clinical trials (efficacy) in which BP has been controlled in 70 to 80% of study participants. Poor BP control exists in spite of six sets of guidelines generated over the last 30 years in the United States. While there are many causes for poor control, several studies have found that physicians are frequently satisfied with uncontrolled BPs. Numerous strategies exist to assist physicians with achieving better BP control, but a consistent, effective approach to solving the problem has not been found.

DESIGN NARRATIVE:

The objective of this study is to test whether BP control can be improved by physician education and feedback provided through the development of physician/pharmacist collaborative teams. The rationale for this proposal is generated from studies demonstrating that physician knowledge, quality of prescribing, and attainment of treatment goals can be improved when physicians collaborate with clinical pharmacists. Previous studies have suffered from insufficient sample size and controls and did not include a structured intervention. This study will address these gaps in knowledge by conducting a randomized, prospective study in 5 clinics (2 intervention and 3 control) with 27 physicians who care for 180 patients with uncontrolled BP. The structured intervention will involve clinical pharmacists who evaluate BP therapy and treatment strategies and make specific recommendations to the physician. Patients will be seen at baseline and at 2, 4, 6, 8, and 9 months, at which time random zero BP measurements will be performed. The specific aims of this study are (1) to determine if better BP control can be achieved by the use of physician/pharmacist teams that utilize physician education and feedback when compared to usual care, (2) to determine if improvements in BP control are related to an increase in physician knowledge of and adherence to BP guidelines when they are involved in physician/pharmacist teams, and (3) to determine if changes in BP control are associated with the level and scope of the physician/pharmacist relationships. This model utilizes an innovative system approach to improve BP control. This intervention has the potential to achieve marked improvements in BP control. This model could become one additional strategy to help achieve the BP goals for Healthy People 2010.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Intervention patients receive care from a clinical pharmacist to improve blood pressure.

Group Type EXPERIMENTAL

Physician/Pharmacist Collaborative Teams

Intervention Type OTHER

The patient's physician collaborates with a clinical pharmacist to improve management of hypertension

Control

Control patients receive usual care and do not have a clinical pharmacist included in their care.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Physician/Pharmacist Collaborative Teams

The patient's physician collaborates with a clinical pharmacist to improve management of hypertension

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females, age 21-85
* Taking 0-3 antihypertensive medications with no changes in regimen or dose within the past 4 weeks
* Non-diabetic with clinic BP 145-179 / 95-109 or diabetic with BP greater than 135/85

Exclusion Criteria

* Previous 24 hour BP monitoring consult service within the past 6 months
* Stage 3 hypertension greater than 180/110
* Recent MI or stroke within the past 6 months
* Class III or IV congestive heart failure
* Unstable angina
* Uncontrolled atrial fibrillation
* Serious renal disease (serum creatinine greater than 3.5)
* Serious hepatic disease (total bilirubin greater than 3.0)
* Pregnancy
* Poor prognosis with less than a 3 year life expectancy

Minimum Eligible Age

21 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No